Label: information for the user
Twicor 20mg/10mg film-coated tablets
rosuvastatina and ezetimiba
Read this label carefully before starting to take this medication, as it contains important information for you.
6. Contents of the pack and additional information
Twicor contains two different active principles in a film-coated tablet. One of the active principles is rosuvastatina, which belongs to the group of medications known as statins, the other active principle is ezetimiba.
Twicor is a medication used in adult patients to reduce elevated levels of cholesterol, the "bad" cholesterol (LDL cholesterol) and certain fatty substances called triglycerides that circulate in the blood. Additionally, this medication increases the concentrations of the "good" cholesterol (HDL cholesterol). This medication acts by reducing cholesterol in two ways: reducing the cholesterol absorbed in the digestive tract, as well as the cholesterol produced by the body itself.
For most people, elevated cholesterol levels do not affect how they feel since they do not produce any symptoms. However, if left untreated, fatty deposits can accumulate in the walls of blood vessels and narrow them. Sometimes, these narrowed blood vessels can become blocked, cutting off blood supply to the heart or brain, which would cause a heart attack or stroke. By reducing cholesterol levels, the risk of having a heart attack, stroke, or other related health problems can be reduced.
This medication is used in patients who cannot control their cholesterol levels solely with diet. While taking this medication, you must follow a cholesterol-reducing diet. Your doctor may prescribe Twicor if you are already taking rosuvastatina and ezetimiba at the same dosage level.
This medication does not help with weight loss.
Do not take Twicor if:
If you find yourself in any of the above situations (or are unsure), consult your doctor.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Twicor if:
If you find yourself in any of these situations mentioned above (or are unsure): consult your doctor or pharmacist before starting to take any dose of this medication.
In a small number of people, statins can affect the liver. This is detected by a simple test that detects increased levels of liver enzymes in the blood. For this reason, your doctor will usually perform blood tests (liver function test) during treatment with this medication. It is essential that you visit your doctor for the tests.
While taking this medication, your doctor will closely monitor you if you have diabetes or are at risk of developing diabetes. You may be at risk of developing diabetes if you have high blood sugar and fat levels, are overweight, and have high blood pressure.
Children and adolescents
This medication is not recommended for use in children and adolescents under 18 years of age.
Other medications and Twicor
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Inform your doctor if you are taking any of the following medications:
If you visit a hospital or receive treatment for another disease, inform the medical staff that you are taking Twicor.
Pregnancy and breastfeeding
Do not take Twicor if you are pregnant, think you may be pregnant, or intend to become pregnant. If you become pregnant while taking this medication, stop taking it immediately and inform your doctor. Women should use contraceptive methods during treatment with this medication.
Do not take Twicor if you are breastfeeding, as it is unknown whether the medication passes into breast milk.
Driving and operating machinery
This medication is not expected to interfere with your ability to drive or use machinery. However, some people may feel dizzy after taking this medication. If you feel dizzy, do not drive or use machinery.
Twicor contains sodium:This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
This medication is not suitable for starting treatment. The start of treatment or dose adjustments, if necessary, should only be made by taking the active ingredients separately, and once the appropriate doses have been adjusted, it is possible to switch to the appropriate dose of Twicor .
You should follow a low-cholesterol diet and exercise while taking Twicor .
The recommended daily dose for adults is one film-coated tablet.
Take Twicor once a day.
You can take it at any time of the day, regardless of meals. Take the medication every day at the same time. Swallow the film-coated tablets whole with a glass of water.
Regular cholesterol level checks
It is essential that you visit your doctor regularly for cholesterol checks, in order to verify that your cholesterol levels have normalized and are maintained at appropriate levels.
If you take more Twicor than you should
Contact your doctor or the nearest hospital's emergency service as you may need medical assistance.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Twicor
Do not worry, omit the missed dose and take the next scheduled dose at the scheduled time. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Twicor
Consult your doctor if you want to interrupt treatment with this medication. Your cholesterol levels may increase again if you stop taking this medication.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
It is important that you know which side effects may occur.
Stop taking Twicor and seek medical help immediately if you experience any of the following side effects:
Rare side effects (may affect up to 1 in 1,000 people):
Allergic reactions such as swelling of the face, lips, tongue, and/or throat, which may cause difficulty breathing and swallowing, lupus-like syndrome (which includes skin rash, joint disorders, and effects on blood cells) and muscle rupture.
Unjustified muscle aches and cramps that last longer than expected. In rare cases, this may become a potentially fatal muscle damage known as rhabdomyolysis, leading to general discomfort, fever, and kidney failure.
Unknown frequency (cannot be estimated from available data):
Reddish flat spots on the trunk, often with central blisters, skin peeling, mouth ulcers, throat, nose, genital, and eye ulcers. These severe skin eruptions may be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome).
Generalized rash, high body temperature, and swollen lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).
Other side effects
Frequent side effects (may affect up to 1 in 10 people)
Rare side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Very rare side effects (may affect up to 1 in 10,000 people)
Unknown frequency (cannot be estimated from available data)
Consult your doctor if you experience weakness in the arms or legs that worsens after periods of activity, double vision, eyelid drooping, difficulty swallowing, or difficulty breathing.
Reporting side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging or on the container after “CAD”. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from light and moisture.
Medications should not be disposed of through drains or in the trash. Dispose of containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Twicor
Rosuvastatina - Core
Pregelatinized maize starch; Microcrystalline cellulose (E460); Meglumina; Dihydrate calcium hydrogen phosphate (E-341); Crospovidone (E-1202); Anhydrous colloidal silica (E-551); Sodium stearate fumarate.
Ezetimiba - Core
Manitol (E-421); Butylhydroxyanisole (E-320); Sodium lauryl sulfate (E-487); Sodium croscarmellose (E-468); Povidone (K-30) (E-1201); Red iron oxide (E-172); Magnesium stearate (E470 b); Sodium stearate fumarate.
Coating
Hydroxypropyl methylcellulose (E-464); Titanium dioxide (E-171); Macrogol 4000; Red iron oxide (E-172).
Appearance of the product and contents of the package
Twicor 20 mg/10 mg are film-coated, round, pink tablets, 10.7 mm in diameter, smooth on both sides.
Twicor is available in OPA/Al/PVC-Al blister packs of 10, 30, 60, 90 film-coated tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Viatris Healthcare Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Responsible for manufacturing
Pharmadox Healthcare Ltd.
KW20A Kordin Industrial Park
Paola PLA3000
Malta
or
Mylan Hungary Kft.
Mylan utca 1
Komárom, 2900
Hungary
or
McDermott Laboratories Limited T/A Gerard Laboratories T/A Mylan Dublin
Unit 35/36 Baldoyle Industrial Estate
Grange Road
Dublin 13
Ireland
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area with the following names:
ROSUVASTATINE/EZETIMIBE MYLAN HEALTHCARE
Netherlands
ROSUVASTATINE/EZETIMIBE MYLAN
Czech Republic
ROZOR
Bulgaria, Cyprus, Greece, Croatia, Hungary, Slovakia, Slovenia
ROZEIOND
Italy
TWICOR
Czech Republic, Denmark, Finland, France, Ireland, Malta, Portugal, Romania, United Kingdom, Spain
MYROSOR
Belgium, Luxembourg
Sorento
Poland
Last review date of this leaflet: March 2023
The detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)https://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.